{"id":"NCT03539900","sponsor":"Yale University","briefTitle":"Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder","officialTitle":"Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-04-17","primaryCompletion":"2022-04-19","completion":"2023-03-22","firstPosted":"2018-05-29","resultsPosted":"2023-07-24","lastUpdate":"2024-04-03"},"enrollment":89,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Binge-Eating Disorder"],"interventions":[{"type":"DRUG","name":"Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination","otherNames":["Contrave"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"NB Medication","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test the efficacy of naltrexone HCI and bupropion HCI (NB) versus placebo in patients with binge-eating disorder (BED), with or without obesity.","primaryOutcome":{"measure":"Change in Binge Eating Frequency","timeFrame":"Post-treatment (3 months)","effectByArm":[{"arm":"NB Medication","deltaMin":6.4,"sd":10.6},{"arm":"Placebo","deltaMin":5.4,"sd":9.6}],"pValues":[{"comp":"OG000 vs OG001","p":".44"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["Dry Mouth","Constipation","Dizziness","Headache","Nausea"]}}